RT Journal Article
SR Electronic
T1 Increased CRTH2 Expression in Postural Orthostatic Tachycardia Syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.18.24317517
DO 10.1101/2024.11.18.24317517
A1 Achemdey, Julian
A1 Martin, Jose Manuel
A1 Abdallah, Hala
A1 Li, Mian
A1 Nava, Victor E.
A1 Abdallah, Hasan
YR 2024
UL http://medrxiv.org/content/early/2024/11/20/2024.11.18.24317517.abstract
AB Purpose The exact etiology of Postural Orthostatic Tachycardia Syndrome (POTS) is still unknown but is likely heterogeneous and multifaceted, involving autoimmune, neuropathic, hypovolemic, and hyperadrenergic pathways. Recently, more research has been devoted to understanding POTS’s underlying immune etiology. We investigated the potential association between elevated levels of prostaglandin chemoattractant receptors (CRTH2) expressed on T-cells and the clinical manifestations observed in patients with POTS.Methods We performed immunophenotyping using flow cytometry on 20 consecutive patients with POTS confirmed by tilt table testing and compared our findings with healthy controls.Results POTS patients demonstrated an increase in CRTH2 levels on (CD8+) T cells and CD8+/CD45RO+ T cells compared to controls.Conclusions CRTH2 is expressed significantly on TH2 and CD8+ cells in POTS patients compared with controls. Since CRTH2 mediates the action of mast cell degranulation mediators such as PGD2 on TH2 cells it results in the release of inflammatory cytokines and interleukins that cause vasodilation and cellular inflammation with capillary leak, leading to reduced effective intravascular volume and reduced venous return, which are known as potential mechanisms in the pathophysiology of POTS, we conclude that CRTH2 plays an important role in the pathophysiology of POTS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approvals from the Johns Hopkins Review Board and consent from all patients for the use of deidentified data were obtained. Number: IRB00427593 Principal Investigator: Hasan Abdallah IRB Committee: IRB-5 Common Rule Version: The Revised Common Rule 2019I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available upon request.